Delving into the Latest Updates on Perindopril Erbumine with Synapse

The goal of this randomized controlled trial is to assess the effectiveness of ACE inhibitors versus standard care) in reversing asymptomatic heart failure (HF stage-B) and/or diastolic dysfunction during a two-year open-label treatment period for formerly preeclamptic women on:
Reversibility of structural and functional myocardial impairment in asymptomatic HF towards healthy values;
The progression from asymptomatic to symptomatic HF (symptoms scored based on the NYHA criteria);
Cardiovascular performance (volume- and pressure load), cardio metabolic risk factors (glucose metabolism, lipid status, kidney function) and quality of life (questionnaires);
Novel biomarkers and relevant microRNA's indicative for hypertrophy, fibrosis inflammation and ischemia.
Eligible subjects will be counselled and upon informed consent randomized for either medication group (n=65) or care as usual group (n=65). After a complete cardiovascular assessment, medication will be initiated open-labeled (Perindopril 2 mg or no medication). Thereafter, standard medical check-ups (blood pressure, ECG, kidney function, transthoracic cardiac ultrasound, endothelial function, quality of life questionnaires, medical history taking, blood and urine banking) will be performed every six months for two years.
Researchers will compare ACE inhibitor (Perindopril 2 mg) and care as usual (i.e. no medication) to investigate whether ACE inhibitor allows timely recovery after subclinical heart failure.

Start Date26 Mar 2024

Sponsor / Collaborator

Academisch Ziekenhuis Maastricht

[+1]

NCT06213610 / RecruitingPhase 1

Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril (Perindopril Tert-butylamine) 8 mg (Pharmtechnology LLC, Republic of Belarus) and Prestarium® A 10 mg (Perindopril Arginine) 10 mg Tablets (Les Laboratoires Servier Industrie, France) in Healthy Volunteers Under Fasting Conditions

This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Prestarium ® A 10 mg tablets) or the test (Perindopril 8 mg tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.

Start Date09 Jan 2024

Sponsor / Collaborator

Pharmtechnology, LLC

100 Clinical Results associated with Perindopril Erbumine

Login to view more data

100 Translational Medicine associated with Perindopril Erbumine

Login to view more data

100 Patents (Medical) associated with Perindopril Erbumine

Login to view more data

2,162

Literatures (Medical) associated with Perindopril Erbumine

01 Jan 2025·BRAIN RESEARCH

Involvement of Renin-Angiotensin system (RAS) components in mild traumatic brain injury

Article

Author: Lúcio Teixeira, Antônio ; Miranda Kangussu, Lucas ; Simões E Silva, Ana Cristina ; de Barros Fernandes, Heliana ; Guimarães, Pedro Pires Goulart ; de Brito Toscano, Eliana Cristina ; de Barros, João Luís Vieira Monteiro ; Fernandes, Heliana de Barros ; Machado, Caroline Amaral ; da Silva Oliveira, Bruna ; Cristina Simões e Silva, Ana ; Silva de Miranda, Aline ; Amaral Machado, Caroline ; Luís Vieira Monteiro de Barros, João ; Oliveira, Bruna da Silva ; de Miranda, Aline Silva ; Cristina de Brito Toscano, Eliana ; Teixeira, Antonio Lucio ; Pires Goulart Guimarães, Pedro

The Renin Angiotensin System (RAS) plays a pathophysiological role in traumatic brain injury (TBI) but the evidence of its involvement in mild TBI (mTBI) is still limited. We aimed at investigating the levels of components from both the classical and counter-regulatory axis of the RAS in a mTBI animal model. Mice with mTBI displayed enhanced ACE/Ang II/AT₁R axis ipsilateral- and contralaterally to the trauma in the hippocampus and prefrontal cortex during acute (24 and 72 h) and later (30 days) timepoints. Increase in Ang-(1-7) levels alongside reduction in Mas receptor expression in hippocampus and prefrontal cortex was also observed after injury. Conversely, mTBI-mice presented higher expression of AT₂ receptor in the contralateral hippocampus and the ipsilateral prefrontal cortex. Importantly, treatment with telmisartan, an AT₁R blocker, and perindopril, an ACE inhibitor, were able to prevent mTBI-associated locomotor activity impairment and anxiety-like behavior, corroborating the involvement of RAS in the pathophysiology of mTBI. We provided original evidence that components of classical and alternative RAS axes undergo alterations in key brain areas following a mTBI in a time and hemisphere dependent manner. Our findings also open new avenues for investigating the therapeutic potential of RAS components in mTBI.

01 Dec 2024·JOURNAL OF HYPERTENSION

Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial

Review

Author: Hamet, Pavel ; Poulter, Neil ; Mancia, Giuseppe ; Wang, Nelson ; Chalmers, John ; Harrap, Stephen ; Grobbee, Diederick E. ; Harris, Katie ; Marre, Michel ; Woodward, Mark

The Action in Diabetes and Vascular disease: preterAx and diamicroN Controlled Evaluation (ADVANCE) trial investigated the effects of intensive blood pressure (BP) lowering using a fixed combination of perindopril-indapamide versus placebo in type 2 diabetes (T2D). The study showed that combination perindopril-indapamide had significant benefits in reducing cardiovascular, renal, and mortality events, with consistent relative risk reductions across different patient subgroups. Secondary analyses of ADVANCE have identified novel risk markers in T2D including cessation of BP lowering therapy, absent peripheral pulses and cardiac biomarkers to name a few. ADVANCE also shed light on practical aspects of hypertension management, including the limitations of office BP, tolerability of combination BP lowering therapy across the range of BP levels and the interpretation of changes in serum creatinine after treatment initiation. This review article summarizes the findings of ADVANCE and its subsequent substudies, which have been foundational in our understanding of BP management and the use of combination BP lowering therapy in T2D.

01 Nov 2024·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Molecular mechanisms underlying methotrexate-induced intestinal injury and protective strategies

Review

Author: Mohamed, Wafaa R ; Hassanein, Emad H M ; Ali, Gaber F

Abstract:

Methotrexate (MTX) is a folic acid reductase inhibitor that manages various malignancies as well as immune-mediated inflammatory chronic diseases. Despite being frequently prescribed, MTX’s severe multiple toxicities can occasionally limit its therapeutic potential. Intestinal toxicity is a severe adverse effect associated with the administration of MTX, and patients are significantly burdened by MTX-provoked intestinal mucositis. However, the mechanism of such intestinal toxicity is not entirely understood, mechanistic studies demonstrated oxidative stress and inflammatory reactions as key factors that lead to the development of MTX-induced intestinal injury. Besides, MTX causes intestinal cells to express pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which activate nuclear factor-kappa B (NF-κB). This is followed by the activation of the Janus kinase/signal transducer and activator of the transcription3 (JAK/STAT3) signaling pathway. Moreover, because of its dual anti-inflammatory and antioxidative properties, nuclear factor erythroid-2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) has been considered a critical signaling pathway that counteracts oxidative stress in MTX-induced intestinal injury. Several agents have potential protective effects in counteracting MTX-provoked intestinal injury such as omega-3 polyunsaturated fatty acids, taurine, umbelliferone, vinpocetine, perindopril, rutin, hesperidin, lycopene, quercetin, apocynin, lactobacillus, berberine, zinc, and nifuroxazide. This review aims to summarize the potential redox molecular mechanisms of MTX-induced intestinal injury and how they can be alleviated. In conclusion, studying these molecular pathways might open the way for early alleviation of the intestinal damage and the development of various agent plans to attenuate MTX-mediated intestinal injury.Graphical Abstract

6

News (Medical) associated with Perindopril Erbumine

11 Sep 2024

·www.drugs.com

Quadruple Single Pill Superior for Resistant Hypertension

WEDNESDAY, Sept. 11, 2024 -- For patients with resistant hypertension , a quadruple single pill is superior to triple therapy, according to a study presented at the European Society of Cardiology Congress, held from Aug. 30 to Sept. 2 in London. Stefano Taddei, from the University of Pisa in Italy, and colleagues conducted a double-blind, randomized trial involving patients with resistant hypertension. Participants completed an eight-week run-in period during which they received the triple combination of perindopril, indapamide, and amlodipine. Those with uncontrolled blood pressure (BP) after eight weeks while adherent to therapy were randomly allocated to continue the same triple therapy or receive a single-pill combination containing perindopril, indapamide, amlodipine, and bisoprolol. A total of 183 patients from 49 centers in 13 countries were included in the trial. The researchers found that the mean office sitting systolic BP was reduced by 20.67 and 11.32 mm Hg in the quadruple single-pill group and in the triple group, respectively, after eight weeks, with the adjusted difference significant in favor of the quadruple single pill. For the main secondary end point of mean 24-hour ambulatory systolic BP, there was a significant difference for the quadruple single pill versus the triple group (−7.53 mm Hg); in addition, there was a significant difference in favor of the quadruple single-pill group in mean office sitting diastolic BP (−6.14 mm Hg). BP control was achieved by 66.3 and 42.7 percent on the quadruple single pill and on triple therapy, respectively. "The availability of a quadruple single-pill combination that includes bisoprolol could help with non-adherence and provide much-needed effective BP control in patients with resistant or difficult-to-treat hypertension," Taddei said in a statement. Several authors disclosed ties to the pharmaceutical and medical device industry, including Servier, which funded the study. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

21 Feb 2024

·www.biospace.com

Discover this new generic drug in the PERINDOPRIL range

MONTREAL, Feb. 21, 2024 /CNW/ - Pharmascience Canada is proud to announce the launch of pms-PERINDOPRIL-AMLODIPINE (perindopril arginine and amlodipine), a drug indicated for the treatment of mild to moderate essential hypertension in adults aged 18 to 65 for whom combination therapy is appropriate. This oral treatment contains two medicines, perindopril arginine and amlodipine. They work together to control the blood pressure. pms-PERINDOPRIL-AMLODIPINE are available in bottles of 100 tablets and comes in the following dosage forms: 3.5 mg / 2.5 mg (this treatment is indicated for initial therapy in patients with mild to moderate essential hypertension.) 7 mg / 5 mg 14 mg / 10 mg This medication is a generic equivalent of Viacoram MD1. pms-PERINDOPRIL-AMLODIPINE tablets are available at affordable prices. « We are excited to introduce Perindopril Amlodipine to the Canadian market, as it reflects our mission to improve the health and quality of life of Canadians through innovative and high-quality products, » said Mike Dutton, Vice-President and General Manager of Pharmascience Canada. « Perindopril Amlodipine is manufactured in our Canadian facility which is another example of how we leverage our expertise and capabilities to deliver value to our customers and patients. » ABOUT PHARMASCIENCE INC. Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2024, the company was awarded Great Place to Work certification for the third year running. PRVIACORAM®1 is a registered trademark owned by Servier Canada Inc. For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060. SOURCE Pharmascience Inc.

Drug Approval

05 Sep 2023

·www.biospace.com

Pharmascience Canada launches a new generic drug to treat hypertension

[05-September-2023] MONTREAL, Sept. 5, 2023 /CNW/ - pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine / indapamide) is used in adults for the initial treatment of mild to moderate essential hypertension (high blood pressure). pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine/ indapamide) are a combination of perindopril erbumine, an angiotensin converting enzyme (ACE) inhibitor, and indapamide, a chlorosulphamoyl diuretic. These two active ingredients act synergistically to lower blood pressure in hypertensive patients of all ages. pms-PERINDOPRIL-INDAPAMIDE comes in the following dosage forms: Tablets of 2 mg perindopril erbumine/ 0.625 mg indapamide. Tablets of 4 mg perindopril erbumine/ 1.25 mg indapamide. Tablets of 8 mg perindopril erbumine/ 2.5 mg indapamide. pms-PERINDOPRIL-INDAPAMIDE is a generic equivalent to Coversyl® Plus, Coversyl® Plus LD and Coversyl® Plus HD and has the same safety and efficacy as Coversyl®. pms-PERINDOPRIL-INDAPAMIDE tablets are offered at a lower price than brand-name products. "The Pharmascience team is happy to bring to market pms-Perindopril-Indapamide used for the initial treatment of high blood pressure. The availability of pms-Perindopril-Indapamide gives every Canadian an affordable and important treatment option! At Pharmascience, we take tremendous pride in our locally produced medicines and will continue to focus on growing our portfolio with quality medications needed for all Canadians!" - mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada. ABOUT PHARMASCIENCE INC. Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2023, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada's Top Employers for Young People as part of Canada's Top 100 Employers. Pharmascience is now certified as a Great Place to Work for a second year in a row. For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060. Coversyl® Plus, Coversyl® Plus LD and Coversyl® Plus HD are registered trademark owned by Servier Canada Inc. SOURCE Pharmascience Inc.

Drug Approval

100 Deals associated with Perindopril Erbumine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00624	Perindopril Erbumine	C09AA04	DB00790

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	JP	Daiichi Sankyo Co., Ltd.	28 Sep 2005
Heart Failure	CA	Servier Pharmaceuticals LLCStartup	31 Dec 1994
Hypertension	CA	Servier Pharmaceuticals LLCStartup	31 Dec 1994
Agranulocytosis	US	Symplmed Pharmaceuticals LLC	30 Dec 1993
Angioedema	US	Symplmed Pharmaceuticals LLC	30 Dec 1993
Collagen Diseases	US	Symplmed Pharmaceuticals LLC	30 Dec 1993
Coronary Artery Disease	US	Symplmed Pharmaceuticals LLC	30 Dec 1993
Essential Hypertension	US	Symplmed Pharmaceuticals LLC	30 Dec 1993
Myocardial Infarction	US	Symplmed Pharmaceuticals LLC	30 Dec 1993
Renal Insufficiency	US	Symplmed Pharmaceuticals LLC	30 Dec 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 3	CA	Servier Pharmaceuticals LLCStartup	01 Apr 2010
Atrial Fibrillation	Phase 3	CA	Servier Pharmaceuticals LLCStartup	01 Dec 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISN WCN2024	Not Applicable	Diabetes Mellitus \| Kidney Failure, Chronic	155	Perindopril	ssehgzrbft(hkynmoiaoa) = lcsaflgbgm ygvvyktqxz (oqtmckcnvh )	Positive	01 Apr 2024
ESC2023	Phase 3	Essential Hypertension	532	Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5)	xemjqnvdpw(coolrancru) = vanlwzfmvk ggeziuvref (gaxjggmjzr ) View more	Positive	27 Aug 2023
				Perindopril tert-butylamine 4 mg/Indapamide 1.25 mg (P4/I1.25) plus Amlodipine 5 mg (P4/I1.25 +A5)	vmrfatbnuw(jzcfaowpmp) = ixggiqgngx frgkslptfm (vcdrzxwvxg ) View more
ESC2023	Not Applicable	First line	-	Perindopril-based regimens	dbrvefoihu(xbukxtlazh) = aqckvghcjh txvyjzcxma (cynfhlwlmv, 87–8973)	-	27 Aug 2023
				Losartan-based regimens	dbrvefoihu(xbukxtlazh) = qtmmncfija txvyjzcxma (cynfhlwlmv, 104–9365)
ESC2022	Not Applicable	Hypertension Second line	-	Perindopril/amlodipine+indapamide	zbxqkmjuwx(phdxottvup) = 11 adverse reactions dgxfwekkqr (stbmumrmpm )	-	07 Apr 2022
ISRCTN67799751 (Pubmed \| Adv Ther)	Not Applicable	Hypertension	22	Perindopril arginine/indapamide single-pill combination (Pa/I SPC)	czbqcpnqpa(vsgdjeozvx) = ctnjfcpkpc cmxmyqlycy (trtpyvjoyu ) View more	-	01 Dec 2020
ESC2019	Not Applicable	Chronic heart failure metalloproteinase-9 (MMP-9) \| tissue inhibitor of metalloproteinase 1 (TIMP-1) \| E-selectin ... View more	30	Perindopril A 5 mg/day	lnaxqpnjfn(azprpntrcs) = qxqxfteypr nqqzsyuwaa (iyreoxkccv ) View more	-	27 May 2019
				Perindopril A 10 mg/day	lnaxqpnjfn(azprpntrcs) = jltvthngix nqqzsyuwaa (iyreoxkccv ) View more
ESC2018	Not Applicable	Hypertension	796	Perindopril/indapamide/amlodipine fixed-dose combination	pzwdiyxdbg(xeqlqzqewb) = ngoynnwivx oknliapvom (pbejhpmuvh ) View more	-	26 Aug 2018
NCT01669434 (CTgov)	Phase 4	Hypotension	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	xyvkgmfotf(rsahzcmzao) = fccjlbwaov yfdpmrlqnu (yhwhbyccvs, jpdtexiumw - teuisndttx) View more	-	11 Dec 2017
				ACEI continuation (ACEI Continuation)	xyvkgmfotf(rsahzcmzao) = kxzhsepxeb yfdpmrlqnu (yhwhbyccvs, bblunvwxza - pepnnikvur) View more
ESC2017	Not Applicable	Hypertension	-	Perindopril+Atorvastatin	xnedznwsoj(dhhgpanemu) = 4.5% of patients wkoroipmix (bohzfimlle ) View more	-	26 Aug 2017
ESC2016	Not Applicable	Hypertension	-	Free combination of perindopril and amlodipine	wmvnimbrqr(oddomvpiex) = rvhdembpzd vyknzeoeks (lyyaeslqwv )	-	28 Aug 2016
				Fixed dose combination of perindopril and amlodipine	wmvnimbrqr(oddomvpiex) = rtgruqqnls vyknzeoeks (lyyaeslqwv )